Rigel Pharmaceuticals has enrolled the first patient in a Phase I trial to evaluate fostamatinib as a treatment for sickle ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating ...

Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, ...

Rigel Pharmaceuticals (RIGL) announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of ...

Syndax Pharmaceuticals struggles with competitive pressures and market skepticism despite promising drugs and strong cash position. Read more on SNDX here.

Cytonics Corporation, a private biotechnology company developing cutting-edge biologic therapies for musculoskeletal conditions, today announced that the first nine patients in its Phase 1 clinical ...

This article is based on a press release statement from Rigel Pharmaceuticals (NASDAQ:RIGL), Inc. The company maintains a healthy financial position with a current ratio of 1.96 and operates with a ...

The NIH confirmed Memoli’s appointment to STAT by email, despite freezing external communications. After this story was published, an NIH spokesperson forwarded a statement from him, saying ...

Though Memoli is an NIH insider, one source familiar with him noted his perspectives —particularly his opposition to Covid-19 vaccine mandates — make him more of an outsider at the agency.

The meeting was abruptly canceled Wednesday in a terse email from an NIH staff member; I soon heard from colleagues that all such committees, and other related meetings in the grant process that ...

While NIH has contributed roughly $1 million to the program over the years, funds the agency had already sent as part of a two-year contract originally set to end in 2026 could no longer be used.